Dietary Intervention for NSCLC Patients Treated With ICI
Recruiting now NCT05805319
Run by Centre hospitalier de l'Université de Montréal (CHUM) · for 18 and older · All sexes
What this study is about
This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention.
Who can join (things the study team will check)
✅ You may be able to join if…
- Signed, informed consent
- Age 18 years or older
- Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI
- Ability to eat solid foods
🚫 You may not be able to join if…
- Severe dietary allergies (e.g. shellfish, nuts, seafood)
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Where this trial is running
- Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Who to contact
Wiam Belkaid, PhD · 514-890-8000 · wiam.belkaid.chum@ssss.gouv.qc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05805319.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.